142 related articles for article (PubMed ID: 35428493)
1. Rapamycin induces autophagy and apoptosis in Kaposiform hemangioendothelioma primary cells in vitro.
Wang Z; Han Q; Wang J; Yao W; Wang L; Li K
J Pediatr Surg; 2022 Jul; 57(7):1274-1280. PubMed ID: 35428493
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Analysis of mTOR Pathway-Related Proteins in Kaposiform Hemangioendothelioma.
Wang Z; Zheng C; Sun H; Yao W; Li K; Ma Y; Zheng S
Dermatology; 2020; 236(3):262-270. PubMed ID: 31896113
[TBL] [Abstract][Full Text] [Related]
3. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
4. Overexpression Prox1 in HemECs resembles Kaposiform hemangioendothelioma and cytotoxicity of sirolimus in vitro.
Wang J; Han Q; Yan H; Yao W; Wang Z; Li K
J Pediatr Surg; 2021 Jul; 56(7):1203-1210. PubMed ID: 33865602
[TBL] [Abstract][Full Text] [Related]
5. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
6. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.
Oza VS; Mamlouk MD; Hess CP; Mathes EF; Frieden IJ
Pediatr Dermatol; 2016; 33(2):e88-92. PubMed ID: 26864138
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
8. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.
Duan L; Renzi S; Weidman D; Waespe N; Chami R; Manson D; Cada M; Carcao M
J Pediatr Hematol Oncol; 2020 Jan; 42(1):74-78. PubMed ID: 30044355
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
12. Laryngomalacia and complicated, life-threatening mTOR-positive Kaposiform hemangioendothelioma cured by Supraglottoplasty and sirolimus.
Schroeder U; Lauten M; Stichtenoth G; Gebhard MP; Buchholz M; Kaiser MM
Klin Padiatr; 2014 Nov; 226(6-7):362-8. PubMed ID: 24810750
[TBL] [Abstract][Full Text] [Related]
13. Kaposiform hemangioendothelioma: current knowledge and future perspectives.
Ji Y; Chen S; Yang K; Xia C; Li L
Orphanet J Rare Dis; 2020 Feb; 15(1):39. PubMed ID: 32014025
[TBL] [Abstract][Full Text] [Related]
14. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
15. The use of mTOR inhibitors for the treatment of kaposiform hemangioendothelioma. A systematic review.
Maza-Morales M; Valdés-Loperena S; Durán-McKinster LC; García-Romero MT
Pediatr Dermatol; 2023; 40(3):440-445. PubMed ID: 36716766
[TBL] [Abstract][Full Text] [Related]
16. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges.
Zhou J; Li Y; Qiu T; Gong X; Yang K; Zhang X; Zhang Z; Lan Y; Hu F; Peng Q; Zhang Y; Kong F; Chen S; Ji Y
Int J Cancer; 2023 Aug; 153(3):600-608. PubMed ID: 36916140
[TBL] [Abstract][Full Text] [Related]
18. Vincristine and sirolimus in the treatment of kaposiform haemangioendothelioma.
Peng S; Yang K; Xu Z; Chen S; Ji Y
J Paediatr Child Health; 2019 Sep; 55(9):1119-1124. PubMed ID: 30604513
[TBL] [Abstract][Full Text] [Related]
19. Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms.
Iacobas I; Simon ML; Amir T; Gribbin CE; McPartland TG; Kaufman MR; Calderwood S; Nosher JL
Clin Imaging; 2015; 39(3):529-32. PubMed ID: 25662209
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
Wang Y; Kong L; Sun B; Cui J; Shen W
J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
